|
|
 |
| Stemolecule™ Tranylcypromine hydrochloride |
|
| Description |
| Stemolecule™ Tranylcypromine hydrochloride is a non-hydrazine monoamine oxidase inhibitor commonly used as an antidepressant drug1. BHC110/LSD1 is a histone H3 lysine 4 demethylation enzyme with close homology to monoamine oxidases2. Nonselective monoamine oxidase inhibitors potently inhibit nucleosomal demethylation of histone H3 lysine. Tranylcypromine has been shown to inhibit BHC110/LSD1 activity (IC50 < 2 μM). Treatment of P19 embryonal carcinoma cells with tranylcypromine resulted in global increase in H3K4 methylation as well as transcriptional derepression of the pluripotent stem cell marker Oct43. |
| Disclaimer |
| This Stemgent® Product is exclusively distributed by Miltenyi Biotec outside the USA and Israel. |
| Specifications and technical documents |
| Specification SheetsMaterial Safety Data Sheets
|
| |
|
| Figure 1 |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| Stemolecule Tranylcypromine hydrochloride |
- 10 mg
- Stemgent Catalog # 04-0033
130-095-583
|
|
| References |
| 1. Frieling and Bleich (2006) Eur Arch Psychiatry Clin Neurosci 256: 268–273. |
| 2. Metzger et al. (2005) Nature 437: 436–439. |
| 3. Lee et al. (2006) Chem Biol 13: 563–567. |
|
| MACS Stem Cell newsletter |
|
Stay current with important developments in stem cell research by subscribing to
Stem Cell Updates.
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
